Background: Side effects of anti-epileptic drugs (AEDs) have not been adequately documented in trigeminal neuralgia and its variants. The aim of this observational cross-sectional study was to compare the A-B Neuropsychological Assessment Schedule (ABNAS), which measures cognitive side effects to the Adverse Events Profile (AEP), which looks at a broader range of side effects, and to investigate drug/ dosage relationships with questionnaire scores to help determine a point at which a drug change would be indicated.
| INTRODUCTION
Trigeminal neuralgia (TN) is a condition characterized by recurrent unilateral episodes of electric shock-like pain, lasting from a few seconds to minutes in the distribution of the trigeminal nerve. 1 The pain is often provoked by a slight and innocuous stimulus, such as touch.
TN is usually idiopathic but can present as a consequence of vascular abnormalities, tumours and multiple sclerosis.
There are other groups of conditions that are very similar to TN and in fact may be variants: short unilateral neuralgiform headache with conjunctival redness and tearing (SUNCT) and short unilateral neuralgiform headache with autonomic features (SUNA). First-line drugs for idiopathic TN including SUNCT and SUNA are anti-epileptic drugs (AED), most commonly carbamazepine or oxcarbazepine. 3 Alternative AEDs have been shown to be effective in TN, including lamotrigine, 4 gabapentin, 5 pregabalin 6 and baclofen. 7 SUNCT
and SUNA seem to respond particularly well to lamotrigine. 2 Surgical treatment options for TN include microvascular decompression, stereotactic radiosurgery and percutaneous procedures such as glycerol rhizotomy, balloon compression and radiofrequency thermocoagulation. 
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Medical treatment is perceived by patients as being a safer option and associated with fewer complications which are usually reversible, in contrast to surgery, which can have significant irreversible complications. This leads most patients and clinicians to lean towards a conservative treatment. 9 However, this choice is made with scarce clinical evidence. One of the main reasons why patients opt for surgery is because of side effects from the AEDs 10 but little work has been done on this topic in TN. A qualitative survey conducted in 2001 11 found that 100% of surveyed TN patients taking AEDs experienced side effects, including drowsiness and cognitive impairment, with a mean of 3 side effects per patient.
A systematic review on carbamazepine performed in 2011 12 reported that 40%-60% of patients would exhibit adverse events, including those mentioned above, as well as gastrointestinal symptoms, headaches, dry mouth or taste change, and mood changes. Other reviews highlight the same problem. [13] [14] [15] [16] [17] [18] However, none of these include information on how the adverse events were measured or whether they were quantified or compared between drugs in any way.
A recent systematic review looking at adverse events assessment on trials of gabapentin and pregabalin in post-operative pain highlighted that adverse event assessment method was not described in 18% of studies, and 8 of 90 studies did not report on adverse events at all.
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In the epilepsy literature, side effects of AEDs are often measured using the Liverpool Adverse Events Profile (AEP) ( Figure S1 ) 20 which has been psychometrically tested. Ranging from 19 to 76, a score of 45 or higher is indicative of toxicity. 21 It has only recently been used to investigate side effects of AEDs in TN. it has not been used in TN patients, nor has a cut-off score for toxic range been calculated yet.
In this study, we aim to use the AEP and ABNAS to quantitatively investigate adverse effects of AEDs used in TN and related conditions, and postulate a toxic range cut-off for the ABNAS.
| MATERIALS & METHODS
| Participants
Participants for this study were identified and consecutively recruited from a facial pain clinic in a London teaching hospital in the period be- 
| Measures
The main measures of interest for this study were total scores of the Pain scores were collected at the start of the outpatient review visit.
Qualitative observations by participants and researchers alike were also obtained. The data were initially entered on an Excel spreadsheet on a secure server. The data were anonymized prior to analysis.
| Statistical analysis
Statistical analysis was conducted using STATA 13 for Windows.
Descriptive statistics were used to characterize the group's demographics, symptomatology, medications used and questionnaire scores.
As drug blood levels were not available for this study, indirect means were used to calculate a possible toxic range cut-off score for ABNAS.
The toxic range cut-off point of the AEP was used to divide the study participants into 2 groups. The mean, median, standard deviation and interquartile ranges of the ABNAS score in the toxic range group were used to approximate a similar cut-off score for ABNAS. For drug and dosage-specific analyses, a comparison of AEP, ABNAS, BPI, HAD-A and HAD-D scores was conducted between single-and multidrug therapy subgroups using appropriate group-wise comparisons where necessary, either t tests or Mann-Whitney U tests depending on the distribution of the measure of interest, in each group or subgroup compared. For the BPI analysis, different mean scores were calculated for each group of BPI questions: mean pain intensity (Q1-Q4), mean general QOL score (Q5a-Q5g) and mean facial score (Q5h-Q5n). Relationships between medication dosage and questionnaire scores were investigated using scatterplots and estimated correlation coefficients, although the study was not powered to assess the statistical significance, if any, of such relationships.
| RESULTS
| Group demographics and questionnaire statistics
As a result of the above-mentioned criteria, 105 patients were selected to be part of the study group. The demographics of this group and group statistics of the measures of interest are listed in Table 1 . The majority of these patients had a diagnosis of trigeminal neuralgia (n = 75), while the rest had other variants of neuropathic pain, such as SUNA (n = 13), trigeminal neuralgia with concomitant pain (n = 6) or in various combinations (n = 11). In terms of medication, 78 patients were on monotherapy, while 27 were on polytherapy. The vast majority were treated with oxcarbazepine, carbamazepine or lamotrigine, as shown in detail in Table 2 ( Figure   S3 ).
| ABNAS toxic range cut-off score
The distributions of AEP and ABNAS scores in the entire patient group are shown in the histograms and boxplots below ( Of the 104 patients who had filled in the AEP questionnaire, 30
fell into the toxic range, as defined by an AEP score higher than 45.
To approximate a similar cut-off for the ABNAS questionnaire, we T calculated the mean and standard error of the ABNAS score in this patient subgroup. We calculated the mean and corresponding 95% confidence interval as 43 (95% CI: 37.4-48.6). Figure 2 shows boxplots of the ABNAS score, stratified by AEP score category (AEP 45 and AEP > 45). A Mann-Whitney U test suggested a significant difference in ABNAS score between these groups (P-value <.001).
| ABNAS subcategories, polytherapy and dosage correlations
In terms of ABNAS subcategories, the questions with highest scores were those in the categories of memory and cognition, while motor complaints were the least common ( Figure 3 ). It seems that distributions of score types are similar for carbamazepine and oxcarbazepine, with oxcarbazepine exhibiting lower scores in all categories ( Figure 3B ).
However, there is more variation for lamotrigine and gabapentin (although we note the small number of patients on each of these drugs).
Comparing single-and multiple drug groups ( Figure 3C ), it looks like there might be lower scores in motor, and perhaps language, categories for the patients on single drugs compared to those on multiple drugs.
When comparing patients that were under a single-drug medication with those taking 2 or more drugs, questionnaire scores tended to be lower for the single-drug group, a difference which was statistically significant in AEP total score (P = .04), but only a trend in ABNAS total This could indicate some dose-related side effects for oxcarbazepine.
The apparent relationships and the disparity between the 2 drugs were still evident when using only participants on monotherapy.
| Qualitative comments
During the study, patients were asked to offer comments on their opinion regarding all 3 questionnaires. Of 47 patients who commented, 23% preferred the AEP questionnaire, 66% the ABNAS and 11% had no preference. Patients who preferred the ABNAS questionnaire found the questions more specific, so they felt sure they were interpreting them correctly. Several patients remarked that despite there being more questions in ABNAS, the overall time taken to fill in the entire questionnaire was shorter as they found that AEP had more general categories in comparison with ABNAS. Another difference noted by patients was that they felt the ABNAS questions purely allowed them to note their cognitive symptoms while the AEP had a more physical focus. Several patients commented that they found that cognitive F I G U R E 4 A, Scatterplots of questionnaire total scores against dosage of CBZ and OXC, with an approximated linear fit and 95% CI. Includes both monotherapy and polytherapy patients. B, Scatterplot of CBZ and OXC dosage against mean score of BPI pain intensity (questions 1-4) with an approximated linear fit and 95% CI. Includes both monotherapy and polytherapy patients symptoms were the most frequently experienced side effect, so they found the ABNAS questionnaire overall more relevant. However, this symptomatology could arise due to both the severity of the pain itself and the anxiety and depression. 30 Finally, the omission of any question addressing double vision in the ABNAS was also noted.
Regarding both questionnaires, in spite of patients being explicitly reminded to base their answers subjectively on medication adverse effects, several said they found it difficult to distinguish drug adverse effects with experiences caused by pain or concurrent medical conditions. Patients on multiple medications in particular had greater difficulty in completing the questionnaires. In one extreme case, a patient on 13 drugs was unable to complete any questions as she found it impossible to distinguish the effects of only her trigeminal neuralgia medication.
Patients responded positively to the aesthetics of the questionnaire and found both simple to interpret. Most patients did not have preference between a landscape or portrait questionnaire layout, though of the 17 that did state a preference, only one preferred a landscape set-up. Reasons behind preferring a portrait layout were due to a dislike for visually scanning longer lines of text on the landscape layout.
| DISCUSSION
In the literature, guidelines or clinical protocols, major emphasis is put Some interesting findings arose when comparing different drugs' side effect profiles, the impact of each one's increase with dosage, and with polytherapy. Qualitatively, it seems that oxcarbazepine is better tolerated than carbamazepine in all categories of side effects.
However, an increase in oxcarbazepine dosage was less tolerated and correlated with higher side effect scores. This was not the case with carbamazepine. Data were collected at least 3 months after treatment onset, so autoinduction of carbamazepine metabolism could be a possible reason for this observation, as it is not known to occur with oxcarbazepine. However, oxcarbazepine metabolites are very similar, and it is possible that this study's sample size is too small to pick up on such changes and subtle differences. Furthermore, without data on serum carbamazepine levels, which are unreliable, it was not possible to test this hypothesis in this study. One possible application of this observation could be that perhaps if a patient under carbamazepine treatment can tolerate its side effects, an increase in dosage could be attempted, with a potential for side effects to remain at the same level. The same cannot be easily said about oxcarbazepine based on our results.
In terms of side effect subgroups, lamotrigine and oxcarbazepine seem to have the lowest negative impact on memory. If fatigue is a problem, oxcarbazepine and pregabalin may prove a better option.
Interestingly, in 528 patients using pregabalin for anxiety or panic disorders, the major side effects were dizziness, insomnia for 9% and somnolence in 8.5%. 31 These were not measured with a questionnaire but through self-reporting, with 77% experienced at least one side effect. Finally, our results suggest that when comparing multiple medications with a single agent, there is a tendency for the side effects to increase, particularly in the subcategories of concentration, motor coordination and language, but with low statistical significance.
As these self-complete questionnaires can be filled out in the waiting room prior to consultation, they can provide a better, patientcentred management without necessarily expecting an increase in consultation time. They can lead to further laboratory investigations, be used to monitor side effects over time and determine which drug and dosage are better suited for each patient. Potentially, they could prompt to a switch to other drugs, and/or initiate polytherapy or referral for neurosurgical therapies.
| Limitations
The nature of self-reporting is one of the main limitations of this study, as is often the case with questionnaire research. Pain, well known to being a subjective and therefore complex experience, often influences the reported side effects of medications. Some patients do find difficult to differentiate between symptoms linked with pain of underlying disease, mood and/or medications' side effects, as is evident by the correlation we found between AEP/ABNAS total scores and BPI mean pain intensity. For example, "trouble in their mouth," could be to both the condition itself and the development of the side effect. Depression and anxiety are also known to influence response to treatment and can confound results. Finally, the sample population is lacking in homogeneity. Future studies in the topic will greatly benefit from recruiting a more homogeneous group of patients.
| Future directions
Subjectively, our data set has shown the importance of assessing cognitive functions in patients who are often performing highly complex tasks in their demanding professional lives. It would therefore be important to also develop objective tests using computer-based programs to measure these effects, for example the Kinematic Assessment Tool (KAT). The KAT is a computerized battery of psychometric tests. Information is acquired via a touch-sensitive screen and in addition may also pick up further side effects such as unsteadiness or tremor. 32 Furthermore, the ABNAS questionnaire would also be a useful tool in future studies comparing side effect profiles of centrally and peripherally acting medications.
| CONCLUSION
The ABNAS questionnaire can be a useful tool for monitoring side effects and personalizing treatment, as it depicts patients' side effect profile in more detail and is better focused on common cognitive adverse effects than the questionnaires commonly used today. The present study attempted to quantify side effects more objectively so that clinicians were alerted to switch pharmacotherapy from one agent to another or even to consider surgical solutions as last resort. Polytherapy showed increase in both number and intensity of side effects. Although CBZ and OXC seem to share similar side effect profiles, patients under OXC tended to report less side effects at low dose. However, these seemed to be dose-dependent, than CBZ. ABNAS data also allowed for a more accurate depiction of the types of side effects associated with each drug, through subcategory scores. Evidently, more research is needed to further validate ABNAS total score and subscores as measures of interest, but it could prove advantageous over AEP in similar patient groups to the present. Future research could also incorporate ABNAS and data similar to this study to investigate side effects and quality of life comparing medical and surgical treatments. 
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